A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

15735D419ML00003-TRITON-MWHCOpen (affiliates only)A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)D419ML00003NCT06008093IndustrialAdultTreatmentIIIGlobalOtherMerkhofer, CristinaMedstar Washington Hospital Center : Leila SounnaThoracic/CNS/H&N/ThyroidOncology GroupMHRI Washington Cancer Institute13705Leila SounnaLeila SounnaLeila.Sounna@Medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>